Key Takeaway: Complex has launched its new iOS mobile app, combining the brand's trusted editorial content with an exclusive shopping experience featuring drops from 100+ streetwear and lifestyle ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Abstract: Across diverse scientific disciplines, the methods and algorithms of digital Fourier processing stand as indispensable tools for tackling a spectrum of real-world challenges. At the heart of ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...

Main Street Advisors, Jimmy Iovine, Universal Music Group, and Goldman Sachs are among the investors in the new Complex venture, while BuzzFeed will retain the brand First We Feast. By Alex Weprin ...

Seagen on Thursday inked a strategic collaboration agreement with San Francisco-based Nurix Therapeutics to develop a potentially new class of therapies—called degrader-antibody conjugates—that ...